

Supporting Information

Catalytic cascade aldol–cyclization of tertiary ketone enolates for enantioselective synthesis of keto-esters with C-F quaternary stereogenic center

Wanxing Sha, Lijun Zhang, Wenzhong Zhang, Haibo Mei, Vadim A. Soloshonok,
Jianlin Han* and Yi Pan

	page
1. General information	2
2. General synthetic procedures and experimental methods.....	2
2.1. General procedures for the preparation of racemic-7 for HPLC analysis.....	2
2.2. General procedures for asymmetric detrifluoroacetylyative cascade reaction	2
2.3. General procedures for the SDE tests	3
2.3.1. Achiral gravity-driven column chromatography SDE tests.....	3
3. Characterization data of products 7	3
3.1. Characterization data of products 7	3
4. X-ray crystallography	13
4.1 X-ray crystallography for 7ca	13
5. NMR spectra	14
5.1. NMR spectra of products 7	14
6. HPLC spectra	58
6.1. HPLC spectra of products 7	58
6.2. HPLC spectra of achiral gravity-driven column chromatography SDE tests	80


1. General information

All commercial reagents were used without additional purification unless otherwise specified. Solvents were purified and dried according to standard methods prior to use. All reactions were carried out under a nitrogen atmosphere with dry, freshly distilled solvents under anhydrous conditions, unless otherwise noted. All experiments were monitored by thin layer chromatography (TLC) using UV light as visualizing agent. TLC was performed on pre-coated silica gel plated. Column chromatography was performed using silica gel 60 (300-400 mesh).

^1H NMR (400 MHz), ^{13}C NMR (101 MHz) and ^{19}F NMR (376 MHz) were measured on a Bruker AVANCE III-400 spectrometer. Chemical shifts are reported in ppm (δ) relative to internal tetramethylsilane (TMS, δ 0.0 ppm) or with the solvent reference relative to TMS employed as the internal standard. Data are reported as follows: chemical shift (multiplicity [singlet (s), doublet (d), triplet (t), quartet (q) and multiplet (m)], coupling constants [Hz], integration). Melting points are uncorrected. Values of optical rotation were measured on Rudolph Automatic Polarimeter A21101 at the wavelength of the sodium D-line (589 nm). Infrared spectra were obtained on Bruker Vector 22 in KBr pellets. HRMS were recorded on a LTQ-Orbitrap XL (Thermofisher, U. S. A.). HPLC analysis was performed on Shimadzu SPD-20A using Daicel Chiralpak IC Column.


2. General synthetic procedures and experimental methods

2.1. General procedures for the preparation of **racemic-7** for HPLC analysis



To a solution of α -fluorinated gem-diols **5** (0.1 mmol), methyl *o*-formylbenzoate **4** (0.2 mmol, 2.0 equiv), and LiBr (0.3 mmol, 3.0 equiv) in THF (2 mL), was added Et_3N (0.25 mmol, 2.5 equiv) dropwise at 0°C . After 1.5 h, the reaction was quenched with saturated aqueous NH_4Cl (5 mL) followed by H_2O (20 mL). The organic layer was taken and the aqueous layer was extracted with EtOAc (2×20 mL). The combined organic layers were washed with H_2O (2×50 mL) and brine solution (1×50 mL) and dried with anhydrous Na_2SO_4 , filtered and the solvent was removed to give the crude product, which was purified by column chromatography to afford the corresponding products **racemic-7**.

2.2. General procedures for asymmetric detrifluoroacetylation cascade reaction



The bisoxazoline ligand **L3** (6.7 mg, 0.025 mmol) and Cu(OTf)₂ (7.2 mg, 0.020 mmol) were dissolved in 0.4 mL of anhydrous THF under argon at room temperature and stirred for 2 h. Then, the α -fluorinated gem-diols **5** (0.1mmol) dissolved in 0.3 mL of THF was added, and the solution was stirred for an additional minute followed by addition of 0.2 mmol of methyl *o*-formylbenzoate **4** (2.0 equiv) dissolved in 0.3 mL of THF. The mixture was stirred for another 10 minutes. Finally, Et₃N (25.6 mg, 0.25 mmol, 2.5 equiv) was added dropwise. The mixture was stirred until the α -fluorinated gem-diols **5** disappeared (monitored by TLC). The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (PE:EA = 7:1) to afford products **7**.


2.3. General procedures for the SDE tests

2.3.1. Achiral gravity-driven column chromatography SDE tests

28.7 mg of compound **7aa** (white solid, 8:92 dr, 92% ee) was used as the starting sample for the gravity-driven column chromatography SDE tests over achiral silica gel (45 g, 300-400 mesh) with the mixed solvent system ether acetate-petroleum ether in the ratio 1:15 as the eluent. Column flow rates were targeted to 40 mL/h amounting to total elution times of several hours. Finally 12 × 10 mL aliquots were collected, chiral HPLC analysis of the collected fractions showed that the early eluting fractions were enantiomerically enriched in comparison to the starting sample while the later eluting fractions were enantiomerically depleted. The ee values of the first and last fractions were 94% and 90%.

3. Characterization data of products **7**


3.1. Characterization data of products **7**



(S)-3-((R)-2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7aa)


Pale yellow solid, 27.2 mg (92% yield), 92:8 dr, 92% ee, m.p. 140 – 142 °C. [α]₂₀ D = -118.6 (c = 0.12, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 8.11 (dd, *J* = 7.8, 0.8 Hz, 1H), 7.93 (d, *J* = 7.5 Hz, 1H), 7.62- 7.53 (m, 3H), 7.38 (t, *J* = 7.6 Hz, 2H), 7.24 (d, *J* = 7.7 Hz, 1H), 6.25 (d, *J* = 8.8 Hz, 1H),

3.30 – 3.22 (m, 1H), 2.83 (dt, J = 17.1, 4.5 Hz, 1H), 2.45 (ddt, J = 14.5, 10.0, 4.5 Hz, 1H), 1.75 (dddd, J = 36.6, 14.6, 10.9, 5.1 Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -161.27 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 190.5 (d, J = 18.6 Hz), 170.0, 144.6 (d, J = 6.8 Hz), 143.9, 135.0, 134.6, 130.8, 130.1, 129.0, 128.6, 127.5, 126.5 (d, J = 1.9 Hz), 126.2, 124.1, 93.6 (d, J = 184.7 Hz), 81.1 (d, J = 25.0 Hz), 27.7 (d, J = 22.8 Hz), 24.1 (d, J = 5.5 Hz). IR (cm^{-1}): 1776, 1698, 1290, 1219, 1065, 761, 733. HRMS (TOF MS ESI): calcd for $\text{C}_{18}\text{H}_{13}\text{FO}_3\text{Na}^+$ [M+Na]⁺ 319.0741, found 319.0743. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (70:30 hexanes/*i*-PrOH at 1.0 mL/min, λ = 254 nm).



(S)-3-((R)-7-bromo-2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7ba)


White solid, 26.7 mg (71% yield), 94:6 dr, 94% ee, m.p. 155 – 156 °C. $[\alpha]_{20} \text{D} = -173.7$ ($c = 0.11$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.20 (d, J = 2.1 Hz, 1H), 7.93 (d, J = 7.5 Hz, 1H), 7.66 – 7.60 (m, 2H), 7.57 (d, J = 7.4 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 6.21 (d, J = 8.5 Hz, 1H), 3.23 – 3.14 (m, 1H), 2.82 (dt, J = 17.3, 4.6 Hz, 1H), 2.52 – 2.39 (m, 1H), 1.74 (dddd, J = 36.4, 14.7, 10.8, 5.1 Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -161.47 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 189.4 (d, J = 18.9 Hz), 169.9, 144.4 (d, J = 6.6 Hz), 142.6, 137.8, 134.7, 132.2, 131.2, 130.8, 130.2, 126.4 (d, J = 1.8 Hz), 126.3, 124.1, 121.4, 93.2 (d, J = 185.0 Hz), 80.9 (d, J = 25.1 Hz), 27.6 (d, J = 22.8 Hz), 23.7 (d, J = 5.6 Hz). IR (cm^{-1}): 1761, 1707, 1054, 1013, 727, 661. HRMS (TOF MS ESI): calcd for $\text{C}_{18}\text{H}_{12}\text{BrFO}_3\text{Na}^+$ [M+Na]⁺ 396.9846, found 396.9804. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (70:30 hexanes/*i*-PrOH at 1.0 mL/min, λ = 254 nm).



(S)-3-((R)-6-chloro-2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7ca)


White solid, 30.3 mg (92% yield), 94:6 dr, 94% ee, m.p. 129 – 130 °C. $[\alpha]_{20} \text{D} = -76.1$ ($c = 0.09$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.03 (d, J = 8.5 Hz, 1H), 7.93 (d, J = 7.4 Hz, 1H), 7.65 – 7.52 (m, 2H), 7.42 – 7.31 (m, 2H), 7.26 – 7.25 (m, 1H), 6.21 (d, J = 8.4 Hz, 1H), 3.30 – 3.17 (m, 1H), 2.83 (dt, J = 17.2, 4.5 Hz, 1H), 2.51 – 2.39 (m, 1H), 1.76 (dddd, J = 36.2, 14.7, 10.8, 5.1 Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -161.25 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 189.5 (d, J = 18.8 Hz), 170.0, 145.4, 144.5 (d, J = 6.6 Hz), 141.7, 134.7, 130.2, 130.2, 129.2, 128.9, 128.1, 126.4 (d, J = 1.8 Hz), 126.2, 124.1, 93.3 (d, J = 184.7 Hz), 81.0 (d, J = 25.3 Hz), 27.7 (d, J = 22.8 Hz), 24.0 (d, J = 5.6 Hz). IR (cm^{-1}): 1773, 1690, 1286, 930, 690, 645. HRMS (TOF MS ESI): calcd for $\text{C}_{18}\text{H}_{12}\text{ClFO}_3\text{Na}^+$ [M+Na]⁺ 353.0351, found 353.0322. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (80:20

hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).




(S)-3-((R)-7-chloro-2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7da)

White solid, 29.2 mg (88% yield), 94:6 dr, 94% ee, m.p. 126 – 128 °C. $[\alpha]_{D}^{20} = -206.9$ ($c = 0.12$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.05 (d, $J = 2.3$ Hz, 1H), 7.94 (d, $J = 7.5$ Hz, 1H), 7.63 (td, $J = 7.5, 1.1$ Hz, 1H), 7.57 (t, $J = 7.4$ Hz, 1H), 7.51 (dd, $J = 8.2, 2.3$ Hz, 1H), 7.38 (d, $J = 7.6$ Hz, 1H), 7.21 (d, $J = 8.3$ Hz, 1H), 6.22 (d, $J = 8.5$ Hz, 1H), 3.27 – 3.15 (m, 1H), 2.84 (dt, $J = 17.2, 4.5$ Hz, 1H), 2.52 – 2.40 (m, 1H), 1.75 (dd, $J = 36.3, 14.7, 10.7, 5.1$ Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -161.49 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 189.5 (d, $J = 18.9$ Hz), 169.9, 144.5 (d, $J = 6.6$ Hz), 142.1, 135.0, 134.7, 133.7, 131.9, 130.6, 130.2, 128.1, 126.4 (d, $J = 1.8$ Hz), 126.2, 124.0, 93.2 (d, $J = 184.9$ Hz), 80.9 (d, $J = 25.2$ Hz), 27.7 (d, $J = 22.8$ Hz), 23.7 (d, $J = 5.6$ Hz). IR (cm^{-1}): 1759, 1705, 1210, 939, 833, 728, 647. HRMS (TOF MS ESI): calcd for $\text{C}_{18}\text{H}_{12}\text{ClFO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 353.0351, found 353.0321. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (70:30 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).




(R)-6-fluoro-5-oxo-6-((S)-3-oxo-1,3-dihydroisobenzofuran-1-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile (7ea)

Pale yellow solid, 15.8 mg (49% yield), 86:14 dr, 93% ee, m.p. 129 – 131 °C. $[\alpha]_{D}^{20} = -75.0$ ($c = 0.10$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.15 (d, $J = 8.1$ Hz, 1H), 7.94 (d, $J = 7.5$ Hz, 1H), 7.66 – 7.56 (m, 4H), 7.41 (d, $J = 7.6$ Hz, 1H), 6.16 (d, $J = 7.7$ Hz, 1H), 3.37 – 3.22 (m, 1H), 2.97 (dt, $J = 17.4, 4.7$ Hz, 1H), 2.53 (qd, $J = 9.5, 4.6$ Hz, 1H), 1.99 – 1.77 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -162.10 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 189.5 (d, $J = 19.2$ Hz), 169.7, 144.4 (d, $J = 5.9$ Hz), 144.3, 134.8, 133.5, 132.9, 130.6, 130.3, 129.2, 126.4, 126.3, 124.0, 118.0, 117.6, 93.2 (d, $J = 185.1$ Hz), 80.7 (d, $J = 25.8$ Hz), 28.0 (d, $J = 22.7$ Hz), 24.0 (d, $J = 6.0$ Hz). IR (cm^{-1}): 1771, 1692, 1052, 920, 734, 721. HRMS (TOF MS ESI): calcd for $\text{C}_{19}\text{H}_{12}\text{FNO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 344.0693, found 344.0694. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).




(S)-3-((R)-5-bromo-2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7fa)

White solid, 33.6 mg (90% yield), 85:15 dr, 95% ee, m.p. 123 – 125 °C. $[\alpha]_{20} D = -50.0$ ($c = 0.10$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.07 (dd, $J = 7.9, 1.1$ Hz, 1H), 7.94 (d, $J = 7.5$ Hz, 1H), 7.82 (dd, $J = 7.9, 1.2$ Hz, 1H), 7.64 (td, $J = 7.5, 1.2$ Hz, 1H), 7.57 (t, $J = 7.3$ Hz, 1H), 7.44 (d, $J = 7.6$ Hz, 1H), 7.30 – 7.27 (m, 1H), 6.17 (d, $J = 8.5$ Hz, 1H), 3.17 – 3.04 (m, 2H), 2.55–2.46 (m, 1H), 1.92 – 1.75 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -162.77 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 189.9 (d, $J = 19.1$ Hz), 169.9, 144.5 (d, $J = 6.1$ Hz), 142.7, 138.8, 134.6, 132.6, 130.2, 128.5, 127.9, 126.5 (d, $J = 1.7$ Hz), 126.2, 124.9, 124.1, 92.8 (d, $J = 185.2$ Hz), 80.7 (d, $J = 25.2$ Hz), 27.3 (d, $J = 22.8$ Hz), 25.0 (d, $J = 5.8$ Hz). IR (cm^{-1}): 1771, 1710, 1052, 922, 738. HRMS (TOF MS ESI): calcd for $\text{C}_{18}\text{H}_{12}\text{BrFO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 396.9846, found 396.9821. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (80:20 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(S)-3-((R)-2-fluoro-7-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7ga)


White solid, 26.0 mg (80% yield), 92:8 dr, 92% ee, m.p. 122 – 124 °C. $[\alpha]_{20} D = -166.7$ ($c = 0.10$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.93 (d, $J = 7.4$ Hz, 1H), 7.65 – 7.50 (m, 3H), 7.39 (d, $J = 7.6$ Hz, 1H), 7.19 – 7.08 (m, 2H), 6.22 (d, $J = 8.8$ Hz, 1H), 3.86 (s, 3H), 3.26 – 3.09 (m, 1H), 2.77 (dt, $J = 16.9, 4.6$ Hz, 1H), 2.44 (qd, $J = 9.3, 4.5$ Hz, 1H), 1.87 – 1.65 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -161.50 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 190.3 (d, $J = 18.7$ Hz), 170.0, 158.8, 144.6 (d, $J = 6.6$ Hz), 136.5, 134.4, 131.4, 130.1, 130.0, 126.4 (d, $J = 1.8$ Hz), 126.0, 123.9, 123.6, 109.9, 93.4 (d, $J = 184.7$ Hz), 81.0 (d, $J = 25.2$ Hz), 55.6, 27.9 (d, $J = 22.7$ Hz), 23.3 (d, $J = 5.5$ Hz). IR (cm^{-1}): 767, 1700, 1289, 1067, 735. HRMS (TOF MS ESI): calcd for $\text{C}_{19}\text{H}_{15}\text{FO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 349.0847, found 349.0825. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (70:30 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(S)-3-((R)-2-fluoro-7-nitro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7gb)


one(7ha)

Pale yellow solid, 17.0 mg (50% yield), 95:5 dr, 92% ee, m.p. 154 – 156 °C. $[\alpha]_{20} D = -173.3$ ($c = 0.15$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.89 (d, $J = 2.4$ Hz, 1H), 8.37 (dd, $J = 8.5$, 2.5 Hz, 1H), 7.94 (d, $J = 7.5$ Hz, 1H), 7.65 (td, $J = 7.5$, 1.1 Hz, 1H), 7.58 (t, $J = 7.4$ Hz, 1H), 7.48 (d, $J = 8.5$ Hz, 1H), 7.43 (d, $J = 7.7$ Hz, 1H), 6.20 (d, $J = 7.7$ Hz, 1H), 3.44 – 3.27 (m, 1H), 3.06 (dt, $J = 17.9$, 4.6 Hz, 1H), 2.59 – 2.51 (m, 1H), 1.97 – 1.74 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -161.78 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 188.9 (d, $J = 19.3$ Hz), 169.7, 150.1, 147.5, 144.3 (d, $J = 6.0$ Hz), 134.8, 131.6, 130.6, 130.4, 128.6, 126.4, 126.3, 124.1, 123.8, 93.0 (d, $J = 185.0$ Hz), 80.6 (d, $J = 25.6$ Hz), 27.7 (d, $J = 22.8$ Hz), 24.5 (d, $J = 5.9$ Hz). IR (cm^{-1}): 1767, 1704, 1344, 1091, 1008, 734. HRMS (TOF MS ESI): calcd for $\text{C}_{18}\text{H}_{12}\text{FNO}_5\text{Na}^+$ [$\text{M}+\text{Na}^+$] 364.0592, found 364.0571. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(S)-3-((R)-2-fluoro-6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7ia)


White solid, 21.5 mg (66% yield), 87:13 dr, 78% ee, m.p. 107 – 109 °C. $[\alpha]_{20} D = -131.3$ ($c = 0.13$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.09 (d, $J = 8.8$ Hz, 1H), 7.92 (d, $J = 7.4$ Hz, 1H), 7.65 – 7.47 (m, 2H), 7.37 (d, $J = 7.6$ Hz, 1H), 6.89 (dd, $J = 8.8$, 2.4 Hz, 1H), 6.66 (d, $J = 2.1$ Hz, 1H), 6.27 (d, $J = 9.0$ Hz, 1H), 3.86 (s, 3H), 3.27 – 3.13 (m, 1H), 2.74 (dt, $J = 17.0$, 4.4 Hz, 1H), 2.40 (ddt, $J = 14.6$, 10.3, 4.4 Hz, 1H), 1.76 – 1.56 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -160.12 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 188.8 (d, $J = 18.3$ Hz), 170.1, 164.9, 146.5, 144.6 (d, $J = 7.2$ Hz), 134.5, 131.1, 129.9, 126.4 (d, $J = 2.0$ Hz), 126.0, 124.2, 124.1, 114.4, 112.4, 93.4 (d, $J = 184.3$ Hz), 81.3 (d, $J = 24.9$ Hz), 55.6, 27.4 (d, $J = 22.9$ Hz), 24.3 (d, $J = 5.1$ Hz). IR (cm^{-1}): 1763, 1682, 1596, 1262, 1219, 922, 729. HRMS (TOF MS ESI): calcd for $\text{C}_{19}\text{H}_{15}\text{FO}_4\text{Na}^+$ [$\text{M}+\text{Na}^+$] 349.0847, found 349.0831. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (70:30 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(S)-3-((R)-6-fluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)isobenzofuran-1(3H)-one (7ja)


White solid, 28.8 mg (93% yield), 97:3 dr, 96% ee, m.p. 149 – 151 °C. $[\alpha]_{20} D = 26.5$ ($c = 0.10$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.90 (d, $J = 7.4$ Hz, 1H), 7.73 – 7.65 (m, 1H), 7.57 (t, $J = 7.6$ Hz, 2H), 7.45 – 7.35 (m, 2H), 7.28 – 7.25 (m, 1H), 7.19 (d, $J = 7.5$ Hz, 1H), 5.97 (d, $J = 15.9$ Hz, 1H), 3.14 (dd, $J = 16.3$, 11.2 Hz, 1H), 2.96 (dd, $J = 16.6$, 7.3 Hz, 1H), 2.46 – 2.15 (m, 3H),

1.91 (tdd, $J = 16.8, 7.7, 4.0$ Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -164.79 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 200.7 (d, $J = 28.9$ Hz), 169.6, 144.6, 141.3 (d, $J = 2.1$ Hz), 136.8, 134.1, 132.0, 130.0, 129.7, 129.1, 127.5, 126.7, 126.0, 123.5, 100.3 (d, $J = 191.1$ Hz), 81.0 (d, $J = 26.3$ Hz), 33.8 (d, $J = 2.4$ Hz), 32.9 (d, $J = 21.5$ Hz), 23.6. IR (cm^{-1}): 1769, 1681, 1596, 1280, 995, 622. HRMS (TOF MS ESI): calcd for $\text{C}_{19}\text{H}_{15}\text{FO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 333.0897, found 333.0880. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldpak IC column (70:30 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(S)-3-((R)-2-fluoro-7-methyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7la)


White solid, 25.0 mg (81% yield), 92:8 dr, 91% ee, m.p. 140 – 142 °C. $[\alpha]_{20} \text{D} = -180.0$ ($c = 0.10$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.93 (d, $J = 8.4$ Hz, 2H), 7.62 – 7.52 (m, 2H), 7.37 (t, $J = 7.9$ Hz, 2H), 7.13 (d, $J = 7.8$ Hz, 1H), 6.24 (d, $J = 8.9$ Hz, 1H), 3.28 – 3.11 (m, 1H), 2.78 (dt, $J = 17.0, 4.5$ Hz, 1H), 2.49 – 2.40 (m, 1H), 2.39 (s, 3H), 1.81 – 1.63 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -161.16 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 190.7 (d, $J = 18.6$ Hz), 170.1, 144.7 (d, $J = 6.9$ Hz), 141.0, 137.3, 136.1, 134.6, 130.6, 130.0, 128.9, 128.5, 126.5 (d, $J = 1.9$ Hz), 126.1, 124.1, 93.6 (d, $J = 184.7$ Hz), 81.2 (d, $J = 24.9$ Hz), 27.7 (d, $J = 22.8$ Hz), 23.7 (d, $J = 5.4$ Hz), 21.1. IR (cm^{-1}): 1763, 1693, 1055, 1018, 732. HRMS (TOF MS ESI): calcd for $\text{C}_{19}\text{H}_{15}\text{FO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 333.0897, found 333.0889. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldpak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(S)-3-((R)-2-fluoro-5-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7ma)


White solid, 17.2 mg (53% yield), 90:10 dr, 91% ee, m.p. 157 – 159 °C. $[\alpha]_{20} \text{D} = -88.2$ ($c = 0.10$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.93 (d, $J = 7.5$ Hz, 1H), 7.70 (d, $J = 7.9$ Hz, 1H), 7.61 (td, $J = 7.5, 0.9$ Hz, 1H), 7.54 (t, $J = 7.4$ Hz, 1H), 7.43 (d, $J = 7.6$ Hz, 1H), 7.34 (t, $J = 8.0$ Hz, 1H), 7.07 (d, $J = 8.1$ Hz, 1H), 3.85 (s, 3H), 2.96 (dd, $J = 9.3, 5.1$ Hz, 2H), 2.45 (ddt, $J = 14.5, 9.5, 4.7$ Hz, 1H), 1.83 – 1.64 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -162.26 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 190.9 (d, $J = 18.8$ Hz), 170.1, 156.8, 144.7 (d, $J = 7.3$ Hz), 134.5, 132.9, 131.7, 130.0, 127.8, 126.6 (d, $J = 1.8$ Hz), 126.2, 124.2, 119.9, 115.6, 93.4 (d, $J = 185.1$ Hz), 81.0 (d, $J = 25.0$ Hz), 55.9, 27.1 (d, $J = 22.8$ Hz), 18.2 (d, $J = 5.8$ Hz). IR (cm^{-1}): 1774, 1711, 1266, 1216, 930, 731, 634. HRMS (TOF MS ESI): calcd for $\text{C}_{19}\text{H}_{15}\text{FO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 349.0847, found 349.0844. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldpak

IC column (80:20 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).




(R)-3-fluoro-3-((S)-3-oxo-1,3-dihydroisobenzofuran-1-yl)chroman-4-one (7na)

Yellow solid, 27.9 mg (94% yield), 95:5 dr, 84% ee, m.p. 125 – 126 °C. $[\alpha]_{20} D = -174.0$ ($c = 0.19$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.00 – 7.90 (m, 2H), 7.63 – 7.51 (m, 3H), 7.40 (d, $J = 7.4$ Hz, 1H), 7.15 – 7.07 (m, 1H), 6.94 (d, $J = 8.4$ Hz, 1H), 6.10 (d, $J = 10.5$ Hz, 1H), 4.63 (dd, $J = 13.1, 11.0$ Hz, 1H), 4.25 (dd, $J = 27.8, 13.1$ Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -167.46 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 185.0 (d, $J = 18.3$ Hz), 169.4, 161.2, 143.5 (d, $J = 5.7$ Hz), 137.7, 134.7, 130.5, 128.0, 126.4, 126.1, 123.7, 122.8, 119.6, 118.3, 90.0 (d, $J = 192.0$ Hz), 79.0 (d, $J = 25.0$ Hz), 68.7 (d, $J = 25.8$ Hz). IR (cm^{-1}): 1771, 1697, 1466, 1218, 1047, 767, 735. HRMS (TOF MS ESI): calcd for $\text{C}_{17}\text{H}_{11}\text{FO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 321.0534, found 321.0533. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (80:20 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(R)-7-bromo-3-fluoro-3-((S)-3-oxo-1,3-dihydroisobenzofuran-1-yl)chroman-4-one (7oa)


White solid, 27.7 mg (74% yield), 94:6 dr, 85% ee, m.p. 141 – 142 °C. $[\alpha]_{20} D = -109.0$ ($c = 0.18$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, $J = 7.1$ Hz, 1H), 7.79 (d, $J = 8.5$ Hz, 1H), 7.69 – 7.53 (m, 2H), 7.41 (d, $J = 7.4$ Hz, 1H), 7.26 – 7.23 (m, 1H), 7.17 (d, $J = 1.7$ Hz, 1H), 6.07 (d, $J = 9.8$ Hz, 1H), 4.66 (dd, $J = 13.2, 11.2$ Hz, 1H), 4.25 (dd, $J = 28.5, 13.2$ Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -167.18 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 184.2 (d, $J = 18.7$ Hz), 169.3, 161.2, 143.4 (d, $J = 5.5$ Hz), 134.8, 132.6, 130.6, 129.1, 126.6, 126.5, 126.0, 123.7, 121.6, 118.4, 89.7 (d, $J = 191.9$ Hz), 78.8 (d, $J = 25.1$ Hz), 69.2 (d, $J = 25.6$ Hz). IR (cm^{-1}): 1767, 1705, 1286, 1009, 701, 607. HRMS (TOF MS ESI): calcd for $\text{C}_{17}\text{H}_{10}\text{BrFO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 398.9639, found 398.9612. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (80:20 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(R)-6-bromo-3-fluoro-3-((S)-3-oxo-1,3-dihydroisobenzofuran-1-yl)chroman-4-one (7pa)


White solid, 26.6 mg (71% yield), 95:5 dr, 86% ee, m.p. 155 – 157 °C. $[\alpha]_{20} D = -155.4$ ($c = 0.13$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.04 (d, $J = 2.3$ Hz, 1H), 7.95 (d, $J = 7.3$ Hz, 1H), 7.66 –

7.57 (m, 3H), 7.40 (d, J = 7.5 Hz, 1H), 6.86 (d, J = 8.9 Hz, 1H), 6.08 (d, J = 10.0 Hz, 1H), 4.65 (dd, J = 13.1, 11.3 Hz, 1H), 4.23 (dd, J = 28.7, 13.2 Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -167.14 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 184.6 (d, J = 18.1 Hz), 168.9, 160.2, 143.5 (d, J = 1.0 Hz), 140.3, 134.8, 130.6, 130.3, 130.3, 126.3, 124.4 (d, J = 2.0 Hz), 120.7, 120.4, 115.6, 89.1 (d, J = 193.2 Hz), 76.9 (d, J = 28.0 Hz), 69.1 (d, J = 27.5 Hz). IR (cm^{-1}): 1780, 1705, 1598, 1474, 1279, 1017, 832, 733. HRMS (TOF MS ESI): calcd for $\text{C}_{17}\text{H}_{10}\text{BrFO}_4\text{Na}^+$ [M+Na] $^+$ 398.9639, found 398.9636. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 254 nm).




(R)-8-chloro-3-fluoro-3-((S)-3-oxo-1,3-dihydroisobenzofuran-1-yl)chroman-4-one (7qa)

Pale yellow solid, 19.8 mg (60% yield), 95:5 dr, 90% ee, m.p. 166 – 167 °C. $[\alpha]_{20} \text{D} = -90.7$ (c = 0.09, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.96 (d, J = 6.9 Hz, 1H), 7.86 (dd, J = 8.0, 1.6 Hz, 1H), 7.69 – 7.54 (m, 3H), 7.43 (d, J = 7.4 Hz, 1H), 7.07 (t, J = 7.9 Hz, 1H), 6.07 (d, J = 9.9 Hz, 1H), 4.79 (dd, J = 13.2, 11.0 Hz, 1H), 4.38 (dd, J = 28.4, 13.2 Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -168.18 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 184.2 (d, J = 18.8 Hz), 169.1, 156.5, 143.3 (d, J = 5.2 Hz), 137.6, 134.6, 130.5, 126.4, 126.4, 126.0 (d, J = 1.3 Hz), 123.5, 123.2, 122.8, 120.7, 89.4 (d, J = 192.3 Hz), 78.5 (d, J = 25.1 Hz), 69.4 (d, J = 25.6 Hz). IR (cm^{-1}): 1760, 1717, 1033, 1024, 722, 712. HRMS (TOF MS ESI): calcd for $\text{C}_{17}\text{H}_{10}\text{ClFO}_4\text{Na}^+$ [M+Na] $^+$ 355.0144, found 355.0121. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (80:20 hexanes/*i*-PrOH at 1.0 mL/min, λ = 254 nm).




(R)-7-chloro-3-fluoro-3-((S)-3-oxo-1,3-dihydroisobenzofuran-1-yl)chroman-4-one (7ra)

White solid, 20.3 mg (61% yield), 96:4 dr, 90% ee, m.p. 134 – 136 °C. $[\alpha]_{20} \text{D} = -137.7$ (c = 0.14, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, J = 7.0 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.68 – 7.54 (m, 2H), 7.41 (d, J = 7.4 Hz, 1H), 7.09 (dd, J = 8.5, 1.8 Hz, 1H), 6.98 (d, J = 1.8 Hz, 1H), 6.07 (d, J = 9.8 Hz, 1H), 4.66 (dd, J = 13.2, 11.2 Hz, 1H), 4.26 (dd, J = 28.5, 13.2 Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -167.13 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 184.0 (d, J = 18.6 Hz), 169.3, 161.4, 144.0, 143.4 (d, J = 5.5 Hz), 134.8, 130.6, 129.2, 126.5, 126.0 (d, J = 1.4 Hz), 123.8, 123.7, 118.5, 118.1, 89.7 (d, J = 191.8 Hz), 78.8 (d, J = 25.1 Hz), 69.2 (d, J = 25.7 Hz). IR (cm^{-1}): 1769, 1707, 1606, 1039, 711, 690. HRMS (TOF MS ESI): calcd for $\text{C}_{17}\text{H}_{10}\text{ClFO}_4\text{Na}^+$ [M+Na] $^+$ 355.0144, found 355.0114. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (80:20 hexanes/*i*-PrOH at 1.0 mL/min, λ = 254 nm).




(R)-3,7-difluoro-3-((S)-3-oxo-1,3-dihydroisobenzofuran-1-yl)chroman-4-one (7sa)

White solid, 24.8 mg (78% yield), 84:16 dr, 73% ee, m.p. 165 – 167 °C. $[\alpha]_{20} D = -157.1$ ($c = 0.11$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.04 – 7.87 (m, 2H), 7.70 – 7.52 (m, 2H), 7.41 (d, $J = 7.4$ Hz, 1H), 6.92 – 6.77 (m, 1H), 6.64 (dd, $J = 9.5, 2.0$ Hz, 1H), 6.09 (d, $J = 9.9$ Hz, 1H), 4.71 – 4.61 (m, 1H), 4.25 (dd, $J = 28.8, 13.2$ Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -96.64 (s, 1F), -166.87 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 183.4 (d, $J = 18.4$ Hz), 169.2, 168.4 (d, $J = 258.0$ Hz), 162.9 (d, $J = 14.0$ Hz), 143.3 (d, $J = 5.7$ Hz), 134.6, 130.6 (d, $J = 11.7$ Hz), 130.4, 126.4, 125.9, 123.6, 116.4 (d, $J = 2.3$ Hz), 111.5 (d, $J = 23.1$ Hz), 105.1 (d, $J = 24.9$ Hz), 89.6 (d, $J = 191.6$ Hz), 78.8 (d, $J = 25.1$ Hz), 69.2 (d, $J = 25.6$ Hz). IR (cm^{-1}): 1766, 1692, 1260, 1043, 1021, 862, 719. HRMS (TOF MS ESI): calcd for $\text{C}_{17}\text{H}_{10}\text{F}_2\text{O}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 339.0439, found 339.0415. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldapak IC column (80:20 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).




(S)-3-((R)-2-fluoro-1-oxo-2,3-dihydro-1H-inden-2-yl)isobenzofuran-1(3H)-one (7ta)

White solid, 26.0 mg (92% yield), 91:9 dr, 59% ee, m.p. 175 – 176 °C. $[\alpha]_{20} D = -84.7$ ($c = 0.14$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.92 (dd, $J = 6.0, 2.5$ Hz, 1H), 7.81 (d, $J = 7.7$ Hz, 1H), 7.62 (t, $J = 7.3$ Hz, 1H), 7.53 (dd, $J = 5.2, 3.5$ Hz, 2H), 7.42 (t, $J = 7.5$ Hz, 1H), 7.37 – 7.20 (m, 2H), 6.03 (d, $J = 9.7$ Hz, 1H), 3.36 (dd, $J = 24.3, 18.3$ Hz, 1H), 3.15 – 3.00 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -155.51 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 197.9 (d, $J = 16.6$ Hz), 169.6, 151.0 (d, $J = 2.6$ Hz), 143.4 (d, $J = 6.7$ Hz), 137.1, 134.5, 134.3, 130.3, 128.7, 126.8, 126.5 (d, $J = 1.7$ Hz), 126.2, 125.1, 123.6, 96.6 (d, $J = 192.2$ Hz), 80.8 (d, $J = 28.5$ Hz), 34.7 (d, $J = 24.6$ Hz). IR (cm^{-1}): 1771, 1718, 1285, 1214, 907, 742. HRMS (TOF MS ESI): calcd for $\text{C}_{17}\text{H}_{11}\text{FO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 305.0584, found 305.0587. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldapak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).




(S)-5-bromo-3-((R)-2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7ab)

White solid, 25.7 mg (69% yield), 80:20 dr, 84% ee, m.p. 134 – 136 °C. $[\alpha]_{20} D = -18.5$ ($c = 0.11$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.09 (d, $J = 7.8$ Hz, 1H), 7.79 – 7.68 (m, 2H), 7.58 (dd, $J = 14.4$, 7.4 Hz, 2H), 7.39 (t, $J = 7.6$ Hz, 1H), 7.27 (d, $J = 6.9$ Hz, 1H), 6.15 (d, $J = 7.9$ Hz, 1H), 3.38 – 3.23 (m, 1H), 2.90 (dt, $J = 17.2$, 4.3 Hz, 1H), 2.48 (qd, $J = 8.9$, 4.1 Hz, 1H), 1.95 – 1.72 (m, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -162.26 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 190.2 (d, $J = 18.9$ Hz), 168.9, 146.5 (d, $J = 6.2$ Hz), 143.6, 135.1, 133.6, 130.5, 129.9, 128.9, 128.6, 127.5, 127.4, 127.2, 125.4 (d, $J = 1.7$ Hz), 93.2 (d, $J = 184.6$ Hz), 80.4 (d, $J = 26.0$ Hz), 28.0 (d, $J = 22.7$ Hz), 24.0 (d, $J = 5.5$ Hz). IR (cm^{-1}): 1764, 1686, 1049, 1009, 916, 764. HRMS (TOF MS ESI): calcd for $\text{C}_{18}\text{H}_{12}\text{BrFO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 396.9846, found 396.9817. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).



(S)-6-bromo-3-((R)-2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isobenzofuran-1(3H)-one (7ac)

White solid, 28.7 mg (77% yield), 87:13 dr, 88% ee, m.p. 123 – 124°C. $[\alpha]_{20} D = -95.6$ ($c = 0.09$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.07 (dd, $J = 7.9$, 1.0 Hz, 1H), 8.05 (d, $J = 1.7$ Hz, 1H), 7.72 (dd, $J = 8.2$, 1.8 Hz, 1H), 7.56 (td, $J = 7.5$, 1.4 Hz, 1H), 7.38 (t, $J = 7.6$ Hz, 1H), 7.31 (d, $J = 8.2$ Hz, 1H), 7.27 – 7.25 (m, 1H), 6.15 (d, $J = 8.1$ Hz, 1H), 3.34 – 3.20 (m, 1H), 2.88 (dt, $J = 17.1$, 4.5 Hz, 1H), 2.47 (ddt, $J = 14.5$, 10.0, 4.5 Hz, 1H), 1.80 (dddd, $J = 37.1$, 14.5, 10.9, 5.2 Hz, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -161.87 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 190.2 (d, $J = 18.7$ Hz), 168.3, 143.7, 143.4 (d, $J = 6.6$ Hz), 137.5, 135.1, 130.5, 129.0, 128.9, 128.5, 128.4 (d, $J = 1.9$ Hz), 127.4, 125.6, 124.2, 93.2 (d, $J = 184.8$ Hz), 81.0 (d, $J = 26.1$ Hz), 28.0 (d, $J = 22.7$ Hz), 24.0 (d, $J = 5.5$ Hz). IR (cm^{-1}): 1778, 1707, 1208, 1124, 1009, 920. HRMS (TOF MS ESI): calcd for $\text{C}_{18}\text{H}_{12}\text{BrFO}_3\text{Na}^+$ $[\text{M}+\text{Na}]^+$ 396.9846, found 396.9815. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiraldak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 254$ nm).





(S)-1-((R)-2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)isochroman-3-one (7ae)

White solid, 25.9 mg (84% yield), 87:13 dr, 94% ee, m.p. 237 – 239 °C. $[\alpha]_{20} D = -17.9$ ($c = 0.16$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.12 (d, $J = 7.9$ Hz, 1H), 7.60 – 7.56 (m, 1H), 7.45 – 7.20 (m, 6H), 5.77 (d, $J = 25.7$ Hz, 1H), 4.10 (d, $J = 19.8$ Hz, 1H), 3.67 (dd, $J = 19.8$, 4.4 Hz, 1H), 3.44 – 3.19 (m, 2H), 2.55 – 2.31 (m, 2H); ^{19}F NMR (376 MHz, CDCl_3) δ -169.48 (s, 1F); ^{13}C NMR (101 MHz, CDCl_3) δ 191.3 (d, $J = 17.8$ Hz), 169.2, 141.1, 134.6, 132.5, 131.4, 129.6, 129.0 (d, $J = 1.8$ Hz), 128.9, 128.3, 127.7, 127.3 (d, $J = 1.4$ Hz), 127.1, 126.1, 97.8 (d, $J = 193.5$ Hz), 80.3 (d, J

= 22.9 Hz), 35.3 (d, J = 7.6 Hz), 30.1 (d, J = 21.4 Hz), 26.4 (d, J = 10.5 Hz). IR (cm^{-1}): 1746, 1694, 1383, 1055, 1031, 758, 729. HRMS (TOF MS ESI): calcd for $\text{C}_{19}\text{H}_{15}\text{FONa}^+ [\text{M}+\text{Na}]^+$ 333.0897, found 333.0885. The dr and ee values were determined by chiral stationary phase HPLC analysis using a Daicel Chiralpak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 254 nm).

4. X-ray crystallography


4.1 X-ray crystallography for **7ca** (CCDC number: 1470631)




5. NMR spectra

5.1. NMR spectra of products 7


^1H NMR (400 MHz, CDCl_3) spectra of 7aa



^{19}F NMR (376 MHz, CDCl_3) spectra of 7aa




¹³C NMR (101 MHz, CDCl₃) spectra of **7aa**




¹H NMR (400 MHz, CDCl₃) spectra of **7ba**




¹⁹F NMR (376 MHz, CDCl₃) spectra of **7ba**




¹³C NMR (101 MHz, CDCl₃) spectra of **7ba**




¹H NMR (400 MHz, CDCl₃) spectra of 7ca




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ca




¹³C NMR (101 MHz, CDCl₃) spectra of **7ca**




¹H NMR (400 MHz, CDCl₃) spectra of **7da**




¹⁹F NMR (376 MHz, CDCl₃) spectra of **7da**




¹³C NMR (101 MHz, CDCl₃) spectra of **7da**




¹H NMR (400 MHz, CDCl₃) spectra of 7ea




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ea




¹³C NMR (101 MHz, CDCl₃) spectra of 7ea




¹H NMR (400 MHz, CDCl₃) spectra of 7fa




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7fa




¹³C NMR (101 MHz, CDCl₃) spectra of **7fa**




¹H NMR (400 MHz, CDCl₃) spectra of 7ga




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ga




¹³C NMR (101 MHz, CDCl₃) spectra of **7ga**




¹H NMR (400 MHz, CDCl₃) spectra of **7ha**




¹⁹F NMR (376 MHz, CDCl₃) spectra of **7ha**




¹³C NMR (101 MHz, CDCl₃) spectra of **7ha**




¹H NMR (400 MHz, CDCl₃) spectra of 7ia




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ia




¹³C NMR (101 MHz, CDCl₃) spectra of **7ia**




¹H NMR (400 MHz, CDCl₃) spectra of 7ja




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ja




^{13}C NMR (101 MHz, CDCl_3) spectra of **7ja**




¹H NMR (400 MHz, CDCl₃) spectra of 7la




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7la




¹³C NMR (101 MHz, CDCl₃) spectra of **7la**




¹H NMR (400 MHz, CDCl₃) spectra of **7ma**




¹⁹F NMR (376 MHz, CDCl₃) spectra of **7ma**




¹³C NMR (101 MHz, CDCl₃) spectra of **7ma**




¹H NMR (400 MHz, CDCl₃) spectra of **7na**




¹⁹F NMR (376 MHz, CDCl₃) spectra of **7na**




¹³C NMR (101 MHz, CDCl₃) spectra of **7na**




¹H NMR (400 MHz, CDCl₃) spectra of **7oa**




¹⁹F NMR (376 MHz, CDCl₃) spectra of **7oa**




¹³C NMR (101 MHz, CDCl₃) spectra of **7oa**




¹H NMR (400 MHz, CDCl₃) spectra of 7pa




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7pa




¹³C NMR (101 MHz, CDCl₃) spectra of **7pa**




¹H NMR (400 MHz, CDCl₃) spectra of 7qa




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7qa




¹³C NMR (101 MHz, CDCl₃) spectra of **7qa**




¹H NMR (400 MHz, CDCl₃) spectra of 7ra




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ra




¹³C NMR (101 MHz, CDCl₃) spectra of **7ra**




¹H NMR (400 MHz, CDCl₃) spectra of 7sa





¹⁹F NMR (376 MHz, CDCl₃) spectra of 7sa




¹³C NMR (101 MHz, CDCl₃) spectra of **7sa**




¹H NMR (400 MHz, CDCl₃) spectra of 7ta




¹³C NMR (101 MHz, CDCl₃) spectra of **7ta**




¹H NMR (400 MHz, CDCl₃) spectra of 7ab




¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ab




¹³C NMR (101 MHz, CDCl₃) spectra of **7ab**




¹H NMR (400 MHz, CDCl₃) spectra of 7ac



¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ac




¹³C NMR (101 MHz, CDCl₃) spectra of 7ac




¹H NMR (400 MHz, CDCl₃) spectra of 7ae



¹⁹F NMR (376 MHz, CDCl₃) spectra of 7ae




¹³C NMR (101 MHz, CDCl₃) spectra of **7ae**




6. HPLC spectra

6.1. HPLC spectra of products 7


HPLC spectra of **racemic-7aa**




HPLC spectra of product **7aa**




HPLC spectra of **racemic-7ba**




HPLC spectra of product **7ba**




HPLC spectra of **racemic-7ca**




HPLC spectra of product **7ca**




HPLC spectra of racemic-7da




HPLC spectra of product 7da




HPLC spectra of racemic-**7ea**




HPLC spectra of product **7ea**




HPLC spectra of **racemic-7fa**




HPLC spectra of product **7fa**




HPLC spectra of **racemic-7ga**




HPLC spectra of product **7ga**




HPLC spectra of **racemic-7ha**




HPLC spectra of product **7ha**




HPLC spectra of **racemic-7ia**




HPLC spectra of product **7ia**




HPLC spectra of **racemic-7ja**




HPLC spectra of product **7ja**




HPLC spectra of **racemic-7la**




HPLC spectra of product **7la**




HPLC spectra of racemic-**7ma**




HPLC spectra of product **7ma**




HPLC spectra of racemic-7na




HPLC spectra of product 7na




HPLC spectra of **racemic-7oa**




HPLC spectra of product **7oa**




HPLC spectra of racemic-7pa




HPLC spectra of product 7pa




HPLC spectra of racemic-7qa




HPLC spectra of product 7qa




HPLC spectra of **racemic-7ra**




HPLC spectra of product **7ra**




HPLC spectra of **racemic-7sa**




HPLC spectra of product **7sa**




HPLC spectra of **racemic-7ta**




HPLC spectra of product **7ta**




HPLC spectra of racemic-7ab




HPLC spectra of product 7ab




HPLC spectra of racemic-**7ac**




HPLC spectra of product **7ac**



HPLC spectra of **racemic-7ae**




HPLC spectra of product **7ae**




6.2. HPLC spectra of achiral gravity-driven column chromatography SDE tests

HPLC spectra of the starting sample:



HPLC spectra of the first fraction:



Detector A Ch1 254nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	16.229	617653	22317	2.892	4.240
2	18.319	248862	7902	1.165	1.501
3	19.856	438669	12863	2.054	2.444
4	25.476	20048648	483305	93.888	91.816
Total		21353832	526387	100.000	100.000

HPLC spectra of the last fraction:

